Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,122 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,536 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (884)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06018883 | Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer(PTCA199-3) | unknown | Phase 3 | 100 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer(OUTREACH) | unknown | Phase 1 | 75 | Mina Alpha LimitedINDUSTRY | 3 | Mar 10, 2025 |
| clinicaltrials |
| NCT06440018 | INSPIRE: a Multi-Cancer Early Detection Study(INSPIRE) | unknown | — | 5,350 | Singlera Genomics Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06773260 | Liver and Spleen Stiffness to Predict the Presence of Esaphageal Varices in Cirrhotic With Advanced HCC(ELASTO-HCC) | unknown | — | 150 | Azienda Ospedaliero Universitaria Policlinico ModenaOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05215665 | GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma | unknown | N/A | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05980403 | Prediction of Lymph Node Status in Stage T1 Esophageal Squamous Cell Carcinoma（RENMIN-237） | unknown | — | 300 | Yongshun ChenOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05042128 | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma(ASCEND) | unknown | Phase 2 | 158 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | Oct 22, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06607120 | Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies | unknown | — | 950 | Zhongda HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06590844 | "cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma | unknown | Phase 4 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06577272 | Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-RFA Recurrence in HCC Patients | unknown | — | 6,000 | Tian'an JiangOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06571396 | Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma | unknown | — | 200 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT02949219 | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | unknown | Phase 2 | 41 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT06540027 | The Effect of Minimally Invasive Surgery on Systemic Inflammatory Response in Rectal Cancer | unknown | — | 80 | Başakşehir Çam & Sakura City HospitalOTHER_GOV | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06463522 | Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06248580 | Find HDV and Determine Its Status in Turkey(SITUHDVATION) | unknown | — | 20,000 | Yaşar Bayındır, MDOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06070636 | bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma | unknown | N/A | 30 | Sun Yat-sen UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06339346 | Analysis of Histopathological Factors Predictive of Lymph Node Involvement and Management Practices in pT1 Colorectal Cancers Treated by Primary Endoscopic Resection(PROMOT1) | unknown | — | 400 | University Hospital, BrestOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06546280 | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation | unknown | Phase 2 | 38 | Zhujiang HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05594927 | Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)(BESTPOP) | unknown | Phase 3 | 261 | Beijing Shenogen Biomedical Co., LtdINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06543030 | Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma | unknown | — | 60 | Assiut UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06540508 | Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma | unknown | — | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04220944 | Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. | unknown | Phase 1 | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04483284 | Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05412589 | mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC | unknown | Phase 2 | 35 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06530784 | Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma | unknown | Phase 2 | 36 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06526832 | A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer | unknown | Phase 1 | 9 | BioSyngen Pte LtdINDUSTRY | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06527495 | Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 150 | Assiut UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06524362 | Effect of Pelvic Rehabilitation After Low Anterior Resection for Cancer Rectum. - A Randomised Controlled Trial(PERECARE) | unknown | N/A | 77 | GEM Hospital & Research CenterOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04823403 | Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma(HIPANIV) | unknown | Phase 1 | 27 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05803928 | Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies | unknown | Phase 1 | 70 | Hua LiOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05883683 | Molecular Study and Precision Medicine for Colorectal Cancer(MSPM) | unknown | — | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06512428 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 138 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06505486 | GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC | unknown | — | 21 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06497777 | The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer | unknown | — | 30 | National Taiwan University HospitalOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT05389527 | Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma(NeoLeap-HCC) | unknown | Phase 2 | 43 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06496789 | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT02355379 | Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over(ADAGE) | unknown | Phase 3 | 774 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03760822 | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients(SOCRATE) | unknown | Phase 2 | 112 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03959293 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | unknown | Phase 2 | 107 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04891900 | TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma | unknown | N/A | 25 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06090656 | Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)(BEST) | unknown | Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06482008 | HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 0 | Jul 1, 2024 | clinicaltrials |
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | unknown | Phase 1 | 63 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Jun 27, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2025source: clinicaltrials